The Ron receptor tyrosine kinase (TK) is overexpressed in many cancers, including prostate cancer. To examine the significance of Ron in prostate cancer in vivo, we utilized a genetically engineered mouse model, referred to as TRAMP mice, that is predisposed to develop prostate tumors. In this model, we show that prostate tumors from 30-week-old TRAMP mice have increased Ron expression compared with age-matched wild-type prostates. Based on the upregulation of Ron in human prostate cancers and in this murine model of prostate tumorigenesis, we hypothesized that this receptor has a functional role in the development of prostate tumors. To test this hypothesis, we crossed TRAMP mice with mice that are deficient in Ron signaling (TKÀ/À). Interestingly, TKÀ/À TRAMP þ mice show a significant decrease in prostate tumor mass relative to TRAMP mice containing functional Ron. Moreover, TKÀ/À TRAMP þ prostate tumors exhibited decreased tumor vascularization relative to TK þ / þ TRAMP þ prostate tumors, which correlated with reduced levels of the angiogenic molecules vascular endothelial growth factor and CXCL2. Although Ron loss did not alter tumor cell proliferation, a significant decrease in cell survival was observed. Similarly, murine prostate cancer cell lines containing a Ron deficiency exhibited decreased levels of active nuclear factor-jB, suggesting that Ron may be important in regulating prostate cell survival at least partly through this pathway. In total, our data show for the first time that Ron promotes prostate tumor growth, prostate tumor angiogenesis and prostate cancer cell survival in vivo.
Introduction
Prostate cancer remains one of the most commonly diagnosed cancers among men in the United States and is a frequent cause of death from cancer in men. Receptor tyrosine kinases (TKs) are emerging as potential therapeutic targets in prostate cancer. For example, inhibition of the epidermal growth factor receptor results in decreased prostate cell proliferation (Vicentini et al., 2003) , and inhibition of the insulin-like growth factor 1 receptor (de Bono et al., 2007; Kojima et al., 2009) or Her2/neu receptor (Agus et al., 1999) reduces tumor growth in mouse prostate cancer cell xenograft models. These data suggest that receptor TKs have an important role in prostate tumor growth and should be considered in the development of new treatments in prostate cancer.
One such potential receptor, the Ron receptor, is a member of the Met family of receptor TKs. Ron is a heterodimeric glycoprotein consisting of an extracellular a-chain and a transmembrane b-chain (Ronsin et al., 1993) . Binding of ligand, hepatocyte growth factor-like protein, to Ron results in receptor dimerization and phosphorylation on important tyrosine residues within the TK domain (Gaudino et al., 1994) . Trans-autophosphorylation also occurs on two tyrosine residues within the carboxyl-domain, resulting in the formation of docking sites for adaptor molecules, including phosphoinositide 3-kinase, phospholipase C-g, Grb2 and Shc. Ron is also upstream of the nuclear factor-kB (NFkB) transcription factor, although the outcome of this regulation is dependent on cell type and context. NF-kB activity is increased in prostate cancer cells compared with non-transformed prostate cells, and has been shown to be an important regulator of angiogenic chemokine production (Shen and Lentsch, 2004) .
Based on the numerous pathways activated by Ron, this receptor has been shown to elicit a multitude of biological responses, including cellular proliferation, migration, scattering, survival and branching morphogenesis (Iwama et al., 1996; Wagh et al., 2008; Meyer et al., 2009b) . The Ron receptor TK has also been implicated in the initiation and progression of several human cancers, including those of the breast, colon, skin and prostate (Maggiora et al., 1998; Chen et al., 2000 ; O'Toole et al., 2006; Thomas et al., 2007) . In human prostate cancer cells, Ron is an important regulator of angiogenic chemokine production. Moreover, the regulation of angiogenic chemokines by the Ron receptor has been shown to at least partially be dependent on the NF-kB transcription factor (Thobe et al., 2010) . Furthermore, Ron-knockdown PC-3 cells orthotopically transplanted into prostates of nude mice resulted in decreased prostate tumor size and vascularization compared with PC-3 control cells (Thobe et al., 2010) . Although this study suggests the importance of Ron in promoting prostate tumor cell growth in vivo, this model does not explain the genetic importance of Ron in the development and progression of prostate cancer.
Mice harboring a deletion of the Ron TK domain, termed Ron TKÀ/À mice, are overtly normal, although they exhibit alterations in inflammatory responses following stress (Waltz et al., 2001) . We have previously published in a skin model of chemically induced carcinogenesis that loss of Ron results in decreased growth of benign skin papillomas, as well as the percent of papillomas that progress to malignancy (Chan et al., 2005) . In addition, Ron TKÀ/À mice crossed with mice that are predisposed to develop mammary tumors display decreased mammary tumor initiation, growth and vascularization . To elucidate the role of the Ron receptor in prostate tumorigenesis in vivo, we generated TRAMP mice that are deficient in Ron signaling (TKÀ/À TRAMP þ mice).
TRAMP mice have expression of the simian virus 40 early genes driven by a prostate-specific rat probasin promoter, specifically expressed in the dorsolateral and ventral lobes of the prostate (Greenberg et al., 1995) . Male TRAMP mice develop prostate hyperplasia as early as 10 weeks of age, and as young as 18 weeks of age can have invasive adenocarcinoma of the prostate. Interestingly, all mice eventually develop metastasis, mainly to the lymph nodes and lungs (Gingrich et al., 1996) .
Utilizing cell lines derived from TRAMP tumors, it has been shown that inhibition of the receptor TK endothelial growth factor receptor results in decreased cell migration, although there is no impact on cellular proliferation (Kassis et al., 1999) . Adult TRAMP male mice treated with Genistein, a phytoestrogen found in soy food known to have TK inhibitory effects, have more well-differentiated prostate tumors compared with control mice . Although these data suggest that receptor TKs are important in prostate tumorigenesis in the TRAMP mouse model, the role of the Ron receptor has not been established. Therefore, in this study we sought to determine the role of Ron in prostate tumor initiation and growth using the TRAMP model.
Results
Wild-type mouse prostates are similar to Ron TKÀ/À prostates Prostates taken from 30-week-old wild-type mice (TK þ / þ ) or age-matched TKÀ/À mice were analyzed by hematoxylin and eosin staining to determine if loss of Ron results in any abnormalities in the prostate. No appreciable differences were observed in any of the lobes of the prostates of TKÀ/À mice compared with controls. Representative prostate tissue from TK þ / þ and TKÀ/À mice is depicted in Figure 1a for the anterior prostate. Additional pictures are provided in Supplementary Figure S1 .
Ron is highly expressed in TRAMP prostate tumors To determine if similar to human prostate disease (O'Toole et al., 2006; Thobe et al., 2010) Ron expression is increased in murine prostate tumors, prostates taken from either 30-week-old wild-type (TK þ / þ ) or agematched TK þ / þ TRAMP þ mice were stained by immunohistochemistry for Ron expression (Figure 1b) . Compared with the minimal expression of Ron observed in the TK þ / þ mouse prostate, TK þ / þ TRAMP þ prostate tumors have significantly elevated levels of Ron. No Ron expression was detected in TKÀ/À prostates (data not shown) or in prostates from TKÀ/À TRAMP þ mice (Figure 1b ). In addition, we analyzed Ron mRNA levels by quantitative real-time PCR and similarly observed increased Ron transcript levels in TK þ / þ TRAMP þ prostates compared with TK þ / þ prostates ( Figure 1c) . No detectable levels of Ron mRNA were found in TKÀ/À prostates or TKÀ/À TRAMP þ prostates (data not shown). Further examination of Ron expression by western analyses shows elevated Ron protein expression in TK þ / þ TRAMP þ prostates relative to wild-type TK þ / þ prostates (Figure 1d ).
Ron TKÀ/À TRAMP þ mice have decreased genitourinary complex and prostate tumor size Thirty-week-old TRAMP mice crossed with mice harboring a targeted deletion of the TK domain of Ron (TKÀ/À TRAMP þ ) showed a significant reduction in genitourinary (GU) complex and prostate size compared with TRAMP mice expressing wild-type Ron (TK þ / þ TRAMP þ ; Figures 2a and b) . The average size of TKÀ/À TRAMP þ prostates was 0.3 g and the GU complex was 1.3 g at 30 weeks of age. TK þ / þ TRAMP þ prostates weighed on average 2.1 g and the GU complex weighed 3.6 g at this same time point. For comparison, prostates and GU weights from TK þ / þ mice were 0.18 ± 0.012 and 0.47 ± 0.035 g, respectively, and did not differ significantly from TKÀ/À mice. As depicted in Figure 2c , TK þ / þ TRAMP þ prostates from 30-week-old mice were composed of poorlydifferentiated prostate cancer characterized by anaplastic sheets of cells with irregular nuclei and very little cytoplasm. Normal glands could be observed within the sheets of anaplastic cells along with associated hemorrhagic areas. A spectrum of pathology ranging from prostatic epithelial neoplasia to well-and poorlydifferentiated adenocarcinoma with lesions staining sporadically for cytokeratin, E-cadherin and synapthophysin were observed in the TK þ / þ TRAMP þ prostates at this time point. In addition, the TK þ / þ TRAMP þ mice had large tumors with the tumors encompassing all or a large fraction of the individual prostate lobes. In contrast, the majority of the TKÀ/À TRAMP þ mice had enlarged prostates with the pathology, including normal, prostatic epithelial neoplasia and well-differentiated adenocarcinoma, and contained a defined glandular architecture with the maintenance of an underlying stroma (Figure 2c ).
Lungs from these mice were also analyzed for metastasis by histological analysis. Three out of seven (43%) TK þ / þ TRAMP þ lungs had detectable lung metastases as depicted in Figure 2d . None of the five TKÀ/À TRAMP þ lungs examined contained metastases and a section of a typical lung from these mice is depicted in Figure 2d . Although the presence of lung metastases is more in the TK þ / þ TRAMP þ mice compared with the TKÀ/À TRAMP þ mice, the data are not significantly different (Po0.09). The lack of significance may be related to the small sample size and warrants further detailed investigation. Interestingly, although Ron has been shown to regulate macrophage activation in acute injury models in vivo (Waltz et al., 2001; Leonis et al., 2002; Wilson et al., 2008) , we examined the extent of macrophage recruitment in the TK þ / þ TRAMP þ and TKÀ/À TRAMP þ prostates and found no appreciable differences in the number of F4/80 þ cells (Supplementary Figure S2) . Although the recruitment of F4/80 þ cells may be similar between genotypes, this does not preclude differences in macrophage activation as having a role in the reduced tumor growth observed in the TKÀ/À TRAMP þ prostates.
Murine TRAMP prostates lacking functional Ron display decreased microvessel density
To determine the extent of prostate vascularization, prostates taken from TRAMP mice containing wild- 
prostates. Data are expressed as means±s.e. *Po0.05 compared with TK þ / þ group. type Ron (TK þ / þ TRAMP þ ) or prostates taken from TKÀ/À TRAMP þ mice were stained with a CD31-specific antibody. TKÀ/À TRAMP þ prostates exhibited a decrease in the number of vessels per unit area compared with TK þ / þ TRAMP þ prostates (Figures 3a and b ). This decrease in microvessel density was correlated with a significant decrease in the levels of vascular endothelial growth factor (VEGF) (Figure 3c) . Moreover, the levels of the pro-angiogenic chemokine CXCL2 were also decreased in TKÀ/À TRAMP þ prostates relative to TK þ / þ TRAMP þ prostates (Figure 3d ), although these data were not statistically significant.
TRAMP prostate tumors from TKÀ/À mice have similar rates of cellular proliferation, but decreased cellular survival Because of the significant difference in tumor size between TK þ / þ TRAMP þ and TKÀ/À TRAMP þ prostate tumors, we sought to determine if there were any differences in cell proliferation or cell death. Interestingly, both TK þ / þ TRAMP þ and TKÀ/À TRAMP þ tumors had similar amount of proliferation as determined by bromodeoxyuridine (BrdU) incorporation and immunohistochemistry (Figures 4a and c) . Staining with a proliferating cell nuclear antigen antibody showed similar results as those based on BrdU incorporation (Supplementary Figure S2B) . There was, however, a significant increase in the number of TdTmediated dUTP nick end labeling (TUNEL)-positive cells in the TKÀ/À TRAMP þ tumors, suggesting that a survival advantage may exist in the TK þ / þ TRAMP þ prostate cancer cells (Figures 4b and c) .
Ron activates NF-kB in prostate cancer Ron inhibition in prostate cancer cells results in decreased activation of NF-kB (Thobe et al., 2010) , and NF-kB is constitutively active in TRAMP mouse prostate tumors (Shukla et al., 2005) . To elucidate a potential mechanism by which Ron may be regulating the viability of the TRAMP prostate epithelial cells, we analyzed levels of NF-kB activity. Figure 5 shows that prostate epithelial cells derived from TKÀ/À TRAMP þ mice have a significant reduction of NF-kB reporter activity compared with prostate epithelial cells derived from TK þ / þ TRAMP þ mice (Figure 5a ). To substantiate decreased NF-kB transcriptional activity in the TKÀ/À TRAMP þ prostates, nuclear extracts were generated from prostate tissue of 30-week-old TKÀ/À TRAMP þ and TK þ / þ TRAMP þ mice and examined by western analysis. A representative experiment is depicted in Figure 5b . The TK þ / þ TRAMP þ prostates consistently displayed increased amounts of nuclear NF-kB relative to TKÀ/À TRAMP þ prostate tissue, further supporting more NF-kB activity in the prostates of TK þ / þ TRAMP þ mice.
Cells derived from TRAMP prostate tumors lacking functional Ron have decreased viability
The increased number of TUNEL-positive cells in Rondeficient TRAMP tumors suggests that Ron signaling may provide a survival advantage. To further examine if cells expressing Ron have increased viability ex vivo, we isolated prostate tumor cells from 30-week-old TK þ / þ TRAMP þ and TKÀ/À TRAMP þ mice. These epithelial cells were then analyzed for plasma membrane integrity by propidium iodide staining and for apoptosis by Annexin V staining utilizing flow cytometry. In examining the tumor cells in complete media or under serum deprivation, no appreciable Annexin V staining was observed under our experimental conditions (data not shown). Similarly, although the TKÀ/À TRAMP þ tumors trended towards increased cleaved caspase-3 staining, there was no significant difference compared with TK þ / þ TRAMP þ tumors (Supplementary Figure S3) . However, consistent with our TUNEL staining, we did observe a consistent and significant increase in the number of dead cells, which lost plasma membrane integrity and were permeable to propidium iodide staining, in the TKÀ/À TRAMP þ group compared with the TK þ / þ TRAMP þ group. The average number of dead TK þ / þ TRAMP þ cells was 6.6 ± 1.36, whereas the average number of dead TKÀ/À TRAMP þ cells was 13.7 ± 1.32 (Supplementary Figure S4) .
Discussion
An analysis of Ron expression in prostate tissue from either wild-type (TK þ / þ ) or age-matched TRAMP mice (TK þ / þ TRAMP þ ) showed that the Ron receptor is highly expressed in prostate tumors relative to normal murine prostate tissue. These data are consistent with several reports documenting increased Ron expression in prostate cancer compared with normal prostate tissue (Dhanasekaran et al., 2005; O'Toole et al., 2006; Lapointe et al., 2007; Thobe et al., 2010) . The overexpression of Ron is an important finding as previous studies have shown that exogenous Ron overexpression is sufficient to induce the formation of both lung and mammary tumors in mice (Chen et al., 2002; Zinser et al., 2006) , and Ron knockdown has been shown to inhibit activation of NF-kB in prostate cancer cell lines (Thobe et al., 2010) .
Our data show for the first time that TRAMP mice deficient in Ron receptor signaling have decreased prostate tumor growth. Similar studies from our laboratory have documented that the Ron receptor is necessary for mammary tumor growth in a polyoma virus middle T (pMT) antigen model of breast cancer. pMT mice deficient in functional Ron were shown to have a longer tumor latency, decreased mammary tumor size and decreased metastasis. However, in the pMT mouse model, a significant decrease in cellular proliferation in Ron-deficient pMT tumors compared with Ronexpressing pMT tumors was observed . In contrast, no appreciable differences in cellular proliferation were observed between 30-week-old TKÀ/À TRAMP þ and TK þ / þ TRAMP þ prostate tumors. These differences may reflect the aggressiveness of the respective tumors, with significant tumor burden observed in the pMT-induced mammary tumor model occurring in o2 months, whereas the TRAMP model was evaluated at 8 months of age.
Although the difference in prostate tumor size in the TK þ / þ TRAMP þ and TKÀ/À TRAMP þ mice did not correlate with differences in tumor cell proliferation, a significant difference in tumor cell viability was observed between groups. Marked increases in the number of TUNEL-positive cells were observed in prostates from TKÀ/À TRAMP þ mice compared with controls, suggesting the novel finding that Ron may be acting as a pro-survival factor in this model. In addition, prostate epithelial cells derived from TKÀ/À TRAMP þ prostates were less viable ex vivo than cells derived from TK þ / þ TRAMP þ prostate, supporting Ron as a regulator of cellular survival, although at present the exact mechanism for these differences remains unclear. Moreover, although no changes were observed in macrophage recruitment in the TK þ / þ TRAMP þ and TKÀ/À TRAMP þ prostates at 30 weeks, this does not preclude the involvement of differential macrophage activation in the TKÀ/À mice as a mechanism that may regulate prostate tumor growth in the TRAMP model. In addition, our studies do not exclude the possibility of the extracellular portion of Ron remaining in the TKÀ/À mice and acting as a dominant negative or a sink for Ron ligand, which may also ultimately impact prostate tumor growth in the TKÀ/À TRAMP þ mice.
The NF-kB transcription factor has been shown to be constitutively active in TRAMP mouse prostate tumors, and correlates with altered IkBa expression and IkB kinase activity (Shukla et al., 2005) . Furthermore, Ron inhibition in prostate cancer cells results in decreased NF-kB activity and a decrease in pro-angiogenic chemokine production (Thobe et al., 2010) . We observed that cells derived from TKÀ/À TRAMP þ prostates have decreased levels of active NF-kB compared with TK þ / þ TRAMP þ -derived cells. Further analysis of the activation of NF-kB in TRAMP prostate specimens showed decreased levels of nuclear NF-kB in TKÀ/À TRAMP þ prostates relative to TK þ / þ TRAMP þ prostates, suggesting that Ron may be acting as a pro-survival factor through the regulation of this pathway.
TKÀ/À TRAMP þ tumors also show a reduction in tumor vascularization compared with TK þ / þ TRAMP þ tumors, suggesting that differences in Figure 5 Ron loss in the TRAMP prostate results in decreased levels of active NF-kB. (a) NF-kB reporter assays performed with prostate cells derived from TK þ / þ TRAMP þ and TKÀ/À TRAMP þ prostates. Decreased NF-kB reporter activity was observed in TKÀ/À TRAMP þ cells compared with TK þ / þ TRAMP þ cells. Relative NF-kB activity for each sample is depicted. Data are expressed as the mean ± s.e. (b) Nuclear extracts from 30-week-old TK þ / þ TRAMP þ and TKÀ/À TRAMP þ prostates were isolated and examined by western analysis. TKÀ/À TRAMP þ prostates exhibit decreased levels of nuclear NF-kB p65 relative to TK þ / þ TRAMP þ prostates. PARP is shown as a nuclear loading control. *Po0.05.
prostate tumor neovascularization may be important for the differences in prostate tumor growth observed in this study. Prostate tumor angiogenesis is important in the TRAMP mouse model as TRAMP mice crossed with mice containing a knockout of the angiogenic chemokine receptor, CXCR2, have decreased prostate tumor growth and time to tumor formation (Shen et al., 2006) . In addition, TRAMP mice treated with soluble VEGF receptor-2 showed decreased prostate tumor volume correlating with decreased vasculature (Becker et al., 2002) . Our previous studies on prostate cancer cell lines showed that all prostate cell lines tested exhibited VEGF expression, although the VEGF levels did not correlate with Ron expression (Thobe et al., 2010) . In addition, we also showed that a Ron knockdown in DU145 or PC-3 prostate cancer cells did not alter VEGF expression in these cells. A knockdown of Ron in pancreatic cell lines also did not lead to changes in VEGF levels (Logan-Collins et al., 2010) . However, the latter studies reported that exogenous administration of the Ron ligand in pancreatic cells was able to stimulate VEGF expression at least at one of the time points examined (Logan-Collins et al., 2010) . These studies suggest that ligand-induced activation of Ron may influence at least temporal VEGF levels, but that decreases in the level of Ron in cancer cell lines, as in the case of the knockdown or knockout cells, does not appear to alter VEGF production. Interestingly, however, studies by Logan-Collins and co-workers show increased CD31 microvessel density staining in human pancreatic xenographs when Ron was knocked down. In contrast, the studies in the accompanying report and published studies consistently showed a significant decrease in CD31 vessel staining in tumors lacking Ron expression Thobe et al., 2010) . In each case however, all tumors containing decreased Ron (prostate or pancreatic) exhibited increases in cell death as indicated by TUNEL staining. Taken together, these data suggest that the effects of Ron signaling on VEGF expression and vascularization are complex and may be influenced possibly by cell type and/or ligand levels and receptor activation. However, a common theme across all findings is the diminished growth of Ron-deficient tumors, which is associated with increases in TUNEL staining. Finally, although we did observe a decrease in VEGF mRNA expression in TKÀ/À TRAMP þ tumors compared with TK þ / þ TRAMP þ tumors, this model represents a loss of Ron in all cell types. VEGF modulation in this model might be influenced by the loss of Ron expression in other cell types (such as macrophages) or by the interaction of cell types in the tumor microenvironment that contain a loss of Ron.
Our studies support the Ron receptor TK as being an important factor for prostate tumor growth in vivo. Further studies are needed to elucidate the potential role of Ron in the growth of prostate cancers, and to determine if advanced prostate cancers upregulate Ron expression to bypass androgen dependence. Our data support the notion that targeting the Ron receptor in prostate cancer has the potential to regulate prostate tumor angiogenesis and prostate cancer survival, and may therefore lead to a reduction in prostate tumor size. Although gene deletion studies such as those presented in this report do not necessarily reflect the response of tumors following targeting Ron pharmacologically, our findings provide the first insight into the Ron receptor signaling system as a potential new therapeutic target in prostate cancer.
Materials and methods

Mice
C57Bl/6 transgenic adenocarcinoma of the mouse prostate mice was purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Mice containing a germline deletion of the Ron TK domain (TKÀ/À) have been characterized previously (Waltz et al., 2001) . TRAMP þ mice were crossed with TKÀ/À mice to generate TK þ /À mice with TRAMP. These latter mice were crossed with TK þ /À mice to obtain wild-type Ron TRAMP mice (TK þ / þ TRAMP þ ) and Rondeficient TRAMP mice (TKÀ/À TRAMP þ ). Only hemizygous TRAMP male mice (here-on referred to as TRAMP þ ) were used for experimental analyses. All animals used were in the C57Bl/6 genetic background. The use and maintenance of animals was performed under protocols approved by the Institutional Animals and Use Committee of the University of Cincinnati. For obtaining weight measurements for the GU complex and the prostate, mice were euthanized and the GU complex (consisting of prostate, seminal vesicles, urethra and bladder) was first removed and weighed. If the bladder was full upon dissection, it was punctured to ensure that the weight was not including urine. The prostate was then dissected from the GU complex and weighed. Measurements are displayed as weight in grams.
Prostate histology and immunohistochemistry
Immunohistochemistry of prostate sections from paraffinembedded 30-week-old wild-type (TK þ / þ ), TKÀ/À, TK þ / þ TRAMP þ or TKÀ/À TRAMP þ prostates were processed as described previously Zinser et al., 2006) . For Ron staining, the Ron C-20 antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied to tissues overnight at 41C. The next day, goat anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA, USA) was added to the tissues, and following amplification with a VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA), positive cells were visualized with 3,3 0 -diaminodbenzidine substrate (Vector Laboratories). The sections were counterstained with hematoxylin, dehydrated and mounted with permount (Fisher Scientific, Pittsburgh, PA, USA). CD31 staining was performed and quantified as described previously (Thobe et al., 2010) , and cleaved caspase-3 staining was performed according to the manufacturer's instructions (1:100 Catalog no. 9664; Cell Signaling Technology, Danvers, MA, USA). F4/80 and proliferating cell nuclear antigen staining was performed as described previously (Mallakin et al., 2006; Meyer et al., 2009a) . For the analysis of proliferation, 2 h before being killed, 30-week-old TK þ / þ TRAMP þ or TKÀ/À TRAMP þ mice were injected intraperitoneally with BrdU and sections from paraffin-embedded prostate tissue were stained utilizing a BrdU staining kit (Amersham, Piscataway, NJ, USA) according to the manufacturer's instructions. Image J software was used to determine the number of positive cells normalized to the area of prostate tissue. For TUNEL analyses, prostate sections from 30-weekold mice were stained using an In situ Cell Death Detection Kit, AP (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's directions, with a 1:2 dilution of TdT enzyme. The number of TUNEL-positive cells was determined by counting as described previously .
Lung metastasis
For the analysis of lung metastases, lungs from 30-week-old TK þ / þ TRAMP þ or TKÀ/À TRAMP þ mice were harvested, fixed in 10% neutral-buffered formalin overnight, processed and were paraffin-embedded. Sections (4 mm) were cut at 50-mm intervals, and were examined by hematoxylin and eosin staining for metastases. Mice were counted as positive for lung metastasis if at least one metastatic focus was observed.
Quantitative real-time PCR RNA was isolated from frozen prostate tissue from 30-weekold mice using the Trizol method (Invitrogen, Carlsbad, CA, USA). The high-capacity complementary DNA kit (Applied Biosystems, Foster City, CA, USA) was used to convert RNA to cDNA as per the manufacturer's instructions, and SYBR green incorporation (Applied Biosystems) was used to measure gene expression. Primer sequences used were as follows: VEGF a forward, GCAGAAGTCCCATGAAGTGA and reverse, TCCAGGGCTTCATCGTTA; CXCL2 forward, AGTG AACTGCGCTGTCAATGC and reverse, AGGCAAACTT TTTGACCGCC. Primers for Ron were described previously (Meyer et al., 2009b) . Gene expression values were normalized to b-glucuronidase (Gus) (forward, TTGAGAACTGGTAT AAGACGCATCAG; reverse, TCTGGTACTCCTCACTGA ACATGC). Relative gene expression values are shown.
Western analyses
For total protein analyses, frozen prostate tissues were homogenized in 1 Â Laemmeli buffer and were briefly sonicated. Nuclear and cytoplasmic extracts were isolated as described previously (Wagh et al., 2011) . Protein concentrations were determined using the MicroBCA kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instructions. A total of 200 mg of protein (for Ron) was loaded into a 6% polyacrylamide gel as described previously (Thobe et al., 2010) . Primary antibodies used were: Ron C-20 (1:200 Santa Cruz Biotechnology), anti-total p65 (Cell Signaling, Boston, MA, USA) and actin (1:40 000 a gift from Dr James Lessard, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA). Membranes were then incubated with a peroxidase-conjugated anti-rabbit or an anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), followed by detection of the antibody with the ECL Plus reagent (Amersham Biosciences, Piscataway, NJ, USA). Protein bands were detected using autoradiography.
Prostate cell isolations
Prostate tumor cells were isolated from prostates of 30-weekold mice and placed into 25 ml digestion media containing Dulbecco's modied Eagle's medium/F12, 1 mg/ml collagenase (Worthington Biochemical, Lakewood, NJ, USA), penicillin/ streptomycin and 2 mg/ml bovine serum albumin (Sigma, St Louis, MO, USA) for approximately 2 h at 37 1C with shaking at 200 r.p.m. Cells were then centrifuged for 5 min at 1000 r.p.m. and supernatant removed. To further dissociate epithelial cells, the pellet was resuspended in Dulbecco's modied Eagle's medium/F12 containing 2 U/ml DNase for 5 min with vigorous shaking. DNase was inactivated with equal volume of Dulbecco's modied Eagle's medium/F12 containing 5% fetal bovine serum. Cells were centrifuged for 5 min at 800 r.p.m., supernatant was removed and pellet was resuspended in 1 Â PBS plus 5% fetal bovine serum. To remove fibroblasts, cells were shaken vigorously, then pulse spun for 10 s to a maximum of 1000 r.p.m.; supernatant was removed and spins were repeated six additional times. Isolated primary tumor cells were utilized before 10 passages and were positive for both cytokeratin expression and androgen receptor status. Purity ranged from 80 to 90%.
NF-kB analyses NF-kB reporter assays, on isolated prostate cancer epithelial cells from TK þ / þ TRAMP þ and TKÀ/À TRAMP þ mice, were performed as described previously (Thobe et al., 2010) . Briefly, 70 000 cells were plated in triplicate in complete media. The next day, cells were transfected using Lipofectamine 2000 (Invitrogen) with either an NF-kB reporter (pNF-kBluc) or an empty vector (pTAL-luc) construct and a control plasmid expressing Renilla (pRL-TK). At 48 h after transfection, the cells were lysed and subjected to a dual luciferase assay according to the manufacturer's protocol (Promega Corporation, Madison, WI, USA). Results are displayed as relative NF-kB reporter activity, where NF-kB luminescence in each sample was normalized to the extent of Renilla expression.
Flow cytometry
At 48 h after plating cells, media were spun to collect any dead or apoptotic cells not adhered to the dish, and adherent cells were collected by trypsinization. The cell pellets were washed with phosphate-buffered saline and binding buffer. Annexin V and propidium iodide were added to the cells according to the manufacturer's instructions (ApoAlert Annexin V-FITC Apoptosis Kit, Clontech, Mountain View, CA, USA). The samples were analyzed using a Coulter Epics XL instrument (Beckman Coulter, Miami, FL, USA).
Statistical analyses
Data are expressed as mean±standard error (s.e.). Student's t-test was used for pair-wise comparisons and Mann-Whitney rank-sum tests were applied when applicable using the SigmaPlot 11.0 software (Systat Software Inc., San Jose, CA, USA). Differences between groups were accepted as significant when Po0.05.
